Interactions of antiparasitic alkaloids with Leishmania protein targets: a molecular docking analysis.

BACKGROUND Leishmaniasis is a collection of chronic diseases caused by protozoa of the genus Leishmania. Current antileishmanial chemotherapeutics have demonstrated adverse side effects and therefore R&D into new safer alternative treatments are needed. METHODS A molecular docking analysis has been carried out to assess possible Leishmania biochemical targets of antiparasitic alkaloids. A total of 209 antiparasitic alkaloids were docked with 24 Leishmania protein targets. RESULTS The strongest docking alkaloid ligands were flinderoles A and B and juliflorine with Leishmania major methionyl-tRNA synthetase; juliflorine, juliprosine, prosopilosidine and prosopilosine with Leishmania mexicana glycerol-3-phosphate dehydrogenase; and ancistrogriffithine A with L. major N-myristoyl transferase. CONCLUSION This molecular docking study has provided evidence for what classes and structural types of alkaloids may be targeting specific Leishmania protein targets.

[1]  Elizabeth Yuriev,et al.  Latest developments in molecular docking: 2010–2011 in review , 2013, Journal of molecular recognition : JMR.

[2]  M. P. Pinheiro,et al.  Crystal structure of dihydroorotate dehydrogenase from Leishmania major. , 2012, Biochimie.

[3]  F. Buckner,et al.  Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization. , 2012, Journal of medicinal chemistry.

[4]  W. Setzer,et al.  The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases - part II. , 2012, Current medicinal chemistry.

[5]  Beáta Flachner,et al.  A Chemocentric Approach to the Identification of Cancer Targets , 2012, PloS one.

[6]  Soizic Prado,et al.  Absolute configuration of 2′(R)-acetylmontrifoline and 2′(R)-montrifoline, furoquinolines from the fruits of Teclea nobilis , 2012 .

[7]  Feng Cong,et al.  Chemical genetics-based target identification in drug discovery. , 2012, Annual review of pharmacology and toxicology.

[8]  Ian H. Gilbert,et al.  Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors , 2011, Journal of medicinal chemistry.

[9]  C. Nakamura,et al.  Recent advances in leishmaniasis treatment. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[10]  R. Wierenga,et al.  High resolution crystal structures of triosephosphate isomerase complexed with its suicide inhibitors: The conformational flexibility of the catalytic glutamate in its closed, liganded active site , 2011, Protein science : a publication of the Protein Society.

[11]  D. Auld,et al.  The Trypanocidal Drug Suramin and Other Trypan Blue Mimetics Are Inhibitors of Pyruvate Kinases and Bind to the Adenosine Site* , 2011, The Journal of Biological Chemistry.

[12]  Ericsson David Coy Barrera,et al.  seco-Limonoids and Quinoline Alkaloids from Raputia heptaphylla and Their Antileishmanial Activity , 2011 .

[13]  F. Buckner,et al.  The double-length tyrosyl-tRNA synthetase from the eukaryote Leishmania major forms an intrinsically asymmetric pseudo-dimer. , 2011, Journal of molecular biology.

[14]  K. Wilson,et al.  The Crystal Structure of the Leishmania major Deoxyuridine Triphosphate Nucleotidohydrolase in Complex with Nucleotide Analogues, dUMP, and Deoxyuridine* , 2011, The Journal of Biological Chemistry.

[15]  Aziz Rahman1,et al.  Antiparasitic and Antimicrobial Indolizidines from the Leaves of Prosopis glandulosa var. glandulosa * , 2011, Planta medica.

[16]  S. Chowdhury,et al.  Cryptolepine-Induced Cell Death of Leishmania donovani Promastigotes Is Augmented by Inhibition of Autophagy , 2011, Molecular biology international.

[17]  Elizabeth Yuriev,et al.  Challenges and advances in computational docking: 2009 in review , 2011, Journal of molecular recognition : JMR.

[18]  F. Buckner,et al.  Structure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate. , 2011, Biochimie.

[19]  R. Arni,et al.  Molecular adaptability of nucleoside diphosphate kinase b from trypanosomatid parasites: stability, oligomerization and structural determinants of nucleotide binding. , 2011, Molecular bioSystems.

[20]  M. P. Pinheiro,et al.  Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery. , 2010, European journal of medicinal chemistry.

[21]  N. Isaacs,et al.  Crystal Structure of Leishmania major Oligopeptidase B Gives Insight into the Enzymatic Properties of a Trypanosomatid Virulence Factor , 2010, The Journal of Biological Chemistry.

[22]  V. Dubey,et al.  Molecular docking studies of selected tricyclic and quinone derivatives on trypanothione reductase of Leishmania infantum , 2010, J. Comput. Chem..

[23]  P. Richomme,et al.  Isoquinolines from the Roots of Thalictrum flavum L. and Their Evaluation as Antiparasitic Compounds , 2010, Molecules.

[24]  V. Avery,et al.  Antiparasitic activity of alkaloids from plant species of Papua New Guinea and Australia. , 2010, International journal of antimicrobial agents.

[25]  R. Wierenga,et al.  Atomic resolution crystallography of a complex of triosephosphate isomerase with a reaction‐intermediate analog: New insight in the proton transfer reaction mechanism , 2010, Proteins.

[26]  L. Brinen,et al.  Crystal Structures of TbCatB and Rhodesain, Potential Chemotherapeutic Targets and Major Cysteine Proteases of Trypanosoma brucei , 2010, PLoS neglected tropical diseases.

[27]  Lukasz Kedzierski,et al.  Leishmaniasis Vaccine: Where are We Today? , 2010, Journal of global infectious diseases.

[28]  Ian H. Gilbert,et al.  N-Myristoyltransferase inhibitors as new leads to treat sleeping sickness , 2010, Nature.

[29]  A. Fournet,et al.  Antileishmanial activity of furoquinolines and coumarins from Helietta apiculata. , 2010, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[30]  Edward W. Tate,et al.  N-Myristoyltransferase from Leishmania donovani: Structural and Functional Characterisation of a Potential Drug Target for Visceral Leishmaniasis , 2010, Journal of molecular biology.

[31]  M. Walkinshaw,et al.  Allosteric Mechanism of Pyruvate Kinase from Leishmania mexicana Uses a Rock and Lock Model* , 2010, The Journal of Biological Chemistry.

[32]  J. Pelletier,et al.  Target identification using drug affinity responsive target stability (DARTS) , 2009, Proceedings of the National Academy of Sciences.

[33]  R. Banerjee,et al.  Structure of cyclophilin from Leishmania donovani bound to cyclosporin at 2.6 A resolution: correlation between structure and thermodynamic data. , 2009, Acta crystallographica. Section D, Biological crystallography.

[34]  L. Costa-Lotufo,et al.  The antitumoral, trypanocidal and antileishmanial activities of extract and alkaloids isolated from Duguetia furfuracea. , 2009, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[35]  P. Mátyus,et al.  Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues. , 2009, Bioorganic & medicinal chemistry.

[36]  Hiroshi Morita,et al.  Cassiarins C-E, antiplasmodial alkaloids from the flowers of Cassia siamea. , 2009, Journal of natural products.

[37]  Adam A. Margolin,et al.  Identifying the proteins to which small-molecule probes and drugs bind in cells , 2009, Proceedings of the National Academy of Sciences.

[38]  M. Tanner,et al.  First generation leishmaniasis vaccines: a review of field efficacy trials. , 2008, Vaccine.

[39]  P. Kumar,et al.  Leishmania donovani pteridine reductase 1: biochemical properties and structure-modeling studies. , 2008, Experimental parasitology.

[40]  J. Wansi,et al.  Bioactive 5alpha-pregnane-type steroidal alkaloids from Sarcococca hookeriana. , 2008, Journal of natural products.

[41]  Norman Stein,et al.  CHAINSAW: a program for mutating pdb files used as templates in molecular replacement , 2008 .

[42]  Glaucius Oliva,et al.  Structural Basis for Selective Inhibition of Trypanosomatid Glyceraldehyde-3-Phosphate Dehydrogenase: Molecular Docking and 3D QSAR Studies , 2008, J. Chem. Inf. Model..

[43]  Maria Paola Costi,et al.  Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development , 2008, Proceedings of the National Academy of Sciences.

[44]  H. Ke,et al.  Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite‐selective inhibitors , 2007, Molecular microbiology.

[45]  R. Huber,et al.  Open and Closed Structures of the UDP-glucose Pyrophosphorylase from Leishmania major* , 2007, Journal of Biological Chemistry.

[46]  R. Banerjee,et al.  Structure of cyclophilin from Leishmania donovani at 1.97 A resolution. , 2007, Acta crystallographica. Section F, Structural biology and crystallization communications.

[47]  J. Soto,et al.  Treatment of New World cutaneous leishmaniasis with miltefosine. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[48]  Brian J. Smith,et al.  Structure of Leishmania mexicana phosphomannomutase highlights similarities with human isoforms. , 2006, Journal of molecular biology.

[49]  K. Brown,et al.  Characterization and selective inhibition of myristoyl-CoA:protein N-myristoyltransferase from Trypanosoma brucei and Leishmania major. , 2006, The Biochemical journal.

[50]  René Thomsen,et al.  MolDock: a new technique for high-accuracy molecular docking. , 2006, Journal of medicinal chemistry.

[51]  A. González-Coloma,et al.  Diterpenoid Alkaloid Derivatives as Potential Chemotherapeutic Agents in American Trypanosomiasis , 2006, Pharmacology.

[52]  J. Berman.  Clinical status of agents being developed for leishmaniasis , 2005, Expert opinion on investigational drugs.

[53]  Stephen M Beverley,et al.  Structures of Leishmania major pteridine reductase complexes reveal the active site features important for ligand binding and to guide inhibitor design. , 2005, Journal of molecular biology.

[54]  P. Mátyus,et al.  Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound. , 2005, Journal of natural products.

[55]  W. Hunter,et al.  Inhibition of Leishmania major pteridine reductase by 2,4,6-triaminoquinazoline: structure of the NADPH ternary complex. , 2004, Acta crystallographica. Section D, Biological crystallography.

[56]  L. Delboni,et al.  The crystal structure of glucose-6-phosphate isomerase from Leishmania mexicana reveals novel active site features. , 2004, European journal of biochemistry.

[57]  Michael I. Jordan,et al.  Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Shyam Sundar,et al.  Oral miltefosine for Indian visceral leishmaniasis. , 2002, The New England journal of medicine.

[59]  C. Mamoun,et al.  Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs. , 2002, Molecular and biochemical parasitology.

[60]  M. Gelb,et al.  Anomalous differences of light elements in determining precise binding modes of ligands to glycerol-3-phosphate dehydrogenase. , 2002, Chemistry & biology.

[61]  Heiko Rischer,et al.  Extract screening by HPLC coupled to MS-MS, NMR, and CD: a dimeric and three monomeric naphthylisoquinoline alkaloids from Ancistrocladus griffithii. , 2002, Phytochemistry.

[62]  S. Croft,et al.  In vitro activity of Triclisia patens and some bisbenzylisoquinoline alkaloids against eishmania donovani and Trypanosoma brucei brucei , 2002, Phytotherapy research : PTR.

[63]  Gordon A. Leonard,et al.  Pteridine reductase mechanism correlates pterin metabolism with drug resistance in trypanosomatid parasites , 2001, Nature Structural Biology.

[64]  A. Fournet,et al.  Bisbenzylisoquinoline alkaloids from Guatteria boliviana (Annonaceae). , 2000, Phytochemistry.

[65]  W G Hol,et al.  A potential target enzyme for trypanocidal drugs revealed by the crystal structure of NAD-dependent glycerol-3-phosphate dehydrogenase from Leishmania mexicana. , 2000, Structure.

[66]  S. Phillips,et al.  The structure of pyruvate kinase from Leishmania mexicana reveals details of the allosteric transition and unusual effector specificity. , 1999, Journal of Molecular Biology.

[67]  V. Schramm,et al.  Nucleoside Hydrolase from Leishmania major , 1999, The Journal of Biological Chemistry.

[68]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[69]  W. Hol,et al.  Crystal structure of Leishmania mexicana glycosomal glyceraldehyde-3-phosphate dehydrogenase in a new crystal form confirms the putative physiological active site structure. , 1998, Journal of molecular biology.

[70]  L. Angenot,et al.  The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells. , 1998, Biochemistry.

[71]  F E Cohen,et al.  Leishmania major: molecular modeling of cysteine proteases and prediction of new nonpeptide inhibitors. , 1997, Experimental parasitology.

[72]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[73]  T. Halgren.  Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[74]  R. Lemmens‐Gruber,et al.  Cardiotoxicity of emetine dihydrochloride by calcium channel blockade in isolated preparations and ventricular myocytes of guinea‐pig hearts , 1996, British journal of pharmacology.

[75]  C L Verlinde,et al.  Crystal structure of glycosomal glyceraldehyde-3-phosphate dehydrogenase from Leishmania mexicana: implications for structure-based drug design and a new position for the inorganic phosphate binding site. , 1995, Biochemistry.

[76]  A. B. Combs,et al.  Effects of pharmacological interventions on emetine cardiotoxicity in isolated perfused rat hearts. , 1995, Toxicology.

[77]  M. Rodnina,et al.  ATPase strongly bound to higher eukaryotic ribosomes. , 1994, European journal of biochemistry.

[78]  W N Hunter,et al.  Structure of trypanothione reductase from Crithidia fasciculata at 2.6 A resolution; enzyme-NADP interactions at 2.8 A resolution. , 1994, Acta crystallographica. Section D, Biological crystallography.

[79]  V. Muñoz,et al.  Effect of some bisbenzylisoquinoline alkaloids on American Leishmania sp. in BALB/c mice , 1993 .

[80]  T. Hunt,et al.  The turnover of methionine in the Met‐tRNA pool and the control of protein synthesis in reticulocyte lysates , 1982, FEBS letters.

[81]  J. Kotźe,et al.  The effect of emetine on metabolism and contractility of the isolated rat heart. , 1969, The Journal of pharmacology and experimental therapeutics.

[82]  W. Setzer,et al.  Antileishmanial Natural Products from Plants , 2012 .

[83]  S. Croft,et al.  Antiparasitic activities of acridone alkaloids from Swinglea glutinosa (Bl.) Merr. , 2009 .

[84]  A. B. Combs,et al.  Emetine inhibits glycolysis in isolated, perfused rat hearts , 2007, Cardiovascular Toxicology.

[85]  D. Söll,et al.  Aminoacyl-tRNA synthesis. , 2000, Annual review of biochemistry.